The primary endpoints of the investigation were the safety and tolerability of multidose MSC administration in study subjects with assessments of MSC-related adverse events (fever, headache, rash, vomiting, diarrhea, and carcinogenesis) and the incidence of allograft rejection, including antibody-mediated rejection (AMR) and acute cellular rejection (ACR), at the 2-year follow-up period. The secondary endpoints were the preliminary observations of MSC efficacy in patients who underwent ABO-i LT compared with rituximab, including (1) the evaluation of graft and recipient survival and (2) the incidence of postoperative complications, including biliary complications and specific infections.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.